• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...



Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P130009 S037/ PAS001
Study Name COMPASSION Cohort
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source Sponsor Registry
Comparison Group No Control
Analysis Type Descriptive
Study Population Child: 2-12 yrs, Adolescent: 13-18 yrs, Transit. Adolescent A (distinctively) : 18-21 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description Continued follow-up of all living subjects who were enrolled under the IDE (G060242). The objective of this PAS is to characterize the clinical outcomes annually through 5 years post-procedure.
Study Population Description All living subjects who were enrolled in the IDE
Sample Size All living subjects
Data Collection The safety and effectiveness endpoints include freedom from device- or procedure-related death or reintervention, freedom from MACCE,

functional improvement (decrease in pulmonary regurgitation, improvement in NYHA functional class, freedom from recurrent pulmonary stenosis), procedural- and device-related adverse events, stent fracture, reintervention on the THV or conduit, and death.

Follow-up Visits and Length of Follow-up 5 years

All subjects are followed at 30 days, 6 months, 12 months, and annually thereafter through 5 years post procedure

COMPASSION Cohort Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 08/29/2016 08/29/2016 On Time
one year report 02/28/2017 02/28/2017 On Time
18 month report 08/29/2017 08/29/2017 On Time
two year report 02/28/2018 02/27/2018 On Time
three year report 02/28/2019 02/27/2019 On Time
unscheduled report 02/28/2020 02/11/2020 On Time
four year report 02/28/2020 02/28/2020 On Time
final report 06/30/2020 06/30/2020 On Time

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Related Links